More than 100 Walgreens Pharmacies Designated Hepatitis C-Specialized to Meet Projected Patient Care Management Needs and Improve Medication Adherence.
With new advances in treatment therapy now available for hepatitis C patients, Walgreens (NYSE:WAG) (Nasdaq:WAG) today announced it is expanding access to Walgreens Connected Caresm hepatitis C program through its more than 100 hepatitis C-specialized pharmacies. Walgreens Connected Care is an education and support plan designed to help patients achieve a sustained virologic response (SVR) and improved quality of life through medication adherence.
Continue reading Walgreens Expands Access to Pharmacist-Led Hepatitis C Care as Treatments Advance
A sustained virologic response to existing hepatitis C treatments — namely, pegylated interferon and ribavirin combined with a protease inhibitor — is less likely to benefit older patients with less advanced liver fibrosis, according to recent data. In light of these findings, older patients may opt to wait for future regimens with fewer adverse effects.
Continue reading Current HCV therapies may not benefit older patients
Right on schedule, Gilead Sciences ($GILD) has submitted its combination hepatitis C treatment for FDA approval, inching toward the era of interferon-free treatment and widening its lead on rival AbbVie ($ABBV).
Gilead handed in an NDA for its fixed-dose cocktail of the NS5A inhibitor ledipasvir and the polymerase inhibitor sofosbuvir, approved on its own last year as Sovaldi.
Continue reading Gilead hands its hep C combo to the FDA as AbbVie race heats up
Some people are genetically equipped to resist HCV’s efforts to turn off a type interferon
The hepatitis C virus (HCV) has a previously unrecognized tactic to outwit antiviral responses and sustain a long-term infection. It also turns out that some people are genetically equipped with a strong countermeasure to the virus’ attempt to weaken the attack on it.
Continue reading Newly found tactics in offense-defense struggle with hepatitis C virus
Coverage of preferred drugs in treatment guidelines, access to expert providers, lower co-pays, and clarity about patient assistance programs are among the steps HIV medical providers and patient advocates recommend to ensure that people with HIV and hepatitis C receive adequate care and treatment under the Affordable Care Act, according to separate statements released this week.
Continue reading Doctors & advocates demand better health coverage for HIV & Hepatitis C